This article is more than 5 years old. Information may no longer be current.

ACC late-breaking clinical trials announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American College of Cardiology announced the late-breaking clinical trials that are scheduled to be presented at its 2019 Scientific Session.

The ACC Scientific Session will be held March 16 to 18 in New Orleans.

In addition to the late-breaking clinical trials, the ACC/American Heart Association Guideline on the Primary Prevention of Cardiovascular Disease will also be released at the meeting.

The ACC has selected the following presentations as late-breakers:

• Apple Heart Study, an assessment of a smartwatch’s ability to identify atrial fibrillation;

• PANACHE, which looks at the safety and efficacy of neladenoson bialanate for the treatment of patients with HF with preserved ejection fraction;

• PIONEER-HF, open-label extension results regarding the initiation of angiotensin receptor-neprilysin inhibition after patients have acute decompensated HF;

• PARTNER 3, a comparison of transcatheter vs. surgical aortic valve replacement in patients who are at low risk;
• Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality, a study looking at the effects of a TAVR platform (Evolut, Medtronic);

• COAPT, which will have two presentations: mitral regurgitation after transcatheter mitral valve repair in patients with HF and secondary mitral regurgitation, and quality of life after the procedure;

• AUGUSTUS, a trial assessing treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), vitamin K antagonist and aspirin or placebo in patients with ACS and AF or PCI;

• MOMENTUM 3, the final analysis of patients who underwent mechanical circulatory support therapy with HeartMate 3 (St. Jude Medical);

• CardioMEMS PAS, which analyzed 1-year outcomes in patients with ambulatory HF who were treated with pulmonary artery pressure-guided therapy;

• a first-in-human randomized trial that focuses on a ticagrelor reversal agent;

• DEFINE PCI, an assessment of residual ischemia after patients underwent successful angiographic PCI;

• CLEAR Wisdom, which analyzed the safety and efficacy of bempedoic acid with maximally tolerated statins in patients with hypercholesterolemia and high CV risk;

• REDUCE-IT, an assessment of total ischemic events in patients treated with icosapent ethyl (Vascepa, Amarin); and

• ODYSSEY OUTCOMES, which assessed total event reduction in patients who were treated with alirocumab (Praluent, Sanofi/Regeneron).

Cardiology Today and Cardiology Today’s Intervention will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.